NextCure Inc (NXTC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.82-0.26%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
NextCure has positive early data for its cancer drug SIM0505. The company aims to fund operations into 2027. It beat earnings in recent quarters. These show progress despite losses.
NextCure is still losing money and has no revenue. Earnings are expected to stay negative. The stock price dropped 86% from its high. This shows weak business momentum.
The market prices in a large decline in growth over 3-5 years. Our fair value is about $10, close to the current price. We see limited upside until earnings improve.
Breaks if: failure to progress SIM0505 Phase 1 trials or start dose optimization
Breaks if: cash runway falls below covering operations into first half 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
NXTC represents a speculative growth investment. The current thesis state is weakened, with recent performance dropping significantly in comparison to its industry peers.
The market currently prices NXTC as cheap compared to its peers, but with a low expectations gap. This suggests that while the stock may appear undervalued, the market is not anticipating significant improvements in performance.
Fundamentals are likely to remain volatile due to ongoing losses and weak recent financial performance. Management is focused on completing a merger and advancing clinical trials, but cash burn remains a concern.
The long-term thesis hinges on management's ability to successfully complete the merger with Avere Therapeutics and advance clinical trials. Additionally, broader sector momentum and economic conditions will play a critical role in shaping NXTC's future.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. NXTC's recent financial performance dropped significantly. It fell from the robust half to the weak half of its sector. The latest earnings report missed expectations, adding to the concerns. The market reaction has been muted since this change.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$7.32 in FY26
In the next 1 to 3 years, NXTC's outlook will depend on execution and external factors, with significant risks present. Not investment advice.